Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

BACKGROUND: Although most non-small-cell lung cancer (NSCLC) patients with the echinoderm microtubule-associated protein-like 4 (EML4) – anaplastic lymphoma kinase (ALK) fusion gene – benefit from ALK tyrosine kinase inhibitors (ALK-TKIs), the efficacy of these drugs varies greatly among individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanizaki, J, Okamoto, I, Takezawa, K, Sakai, K, Azuma, K, Kuwata, K, Yamaguchi, H, Hatashita, E, Nishio, K, Janne, P A, Nakagawa, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322944/
https://www.ncbi.nlm.nih.gov/pubmed/22240786
http://dx.doi.org/10.1038/bjc.2011.586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322944/
https://www.ncbi.nlm.nih.gov/pubmed/22240786
http://dx.doi.org/10.1038/bjc.2011.586

Ejemplares similares